SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-014970
Filing Date
2022-08-05
Accepted
2022-08-05 08:46:43
Documents
79
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-20220630.htm   iXBRL 10-Q 3281690
2 EX-10.1 cadl-ex10_1.htm EX-10.1 137272
3 EX-31.1 cadl-ex31_1.htm EX-31.1 18223
4 EX-31.2 cadl-ex31_2.htm EX-31.2 18975
5 EX-32.1 cadl-ex32_1.htm EX-32.1 10755
6 EX-32.2 cadl-ex32_2.htm EX-32.2 11257
  Complete submission text file 0000950170-22-014970.txt   9699911

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20220630.xsd EX-101.SCH 62687
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cadl-20220630_def.xml EX-101.DEF 245496
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20220630_pre.xml EX-101.PRE 371486
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20220630_lab.xml EX-101.LAB 476991
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cadl-20220630_cal.xml EX-101.CAL 42268
73 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20220630_htm.xml XML 1388846
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 221138776
SIC: 2836 Biological Products, (No Diagnostic Substances)